Previous 10 | Next 10 |
– Third-Quarter Revenue of $989.2 Million – – Third-Quarter GAAP Earnings per Share of $1.88 and Non-GAAP Earnings per Share of $2.63 – – Narrows 2022 Revenue Growth and Earnings Per Share Guidance – – Announces ...
Charles River Laboratories ( NYSE: CRL ) is scheduled to announce Q3 earnings results on Wednesday, November 2nd, before market open. The consensus EPS Estimate is $2.50 (-7.4% Y/Y) and the consensus Revenue Estimate is $970.43M (+8.3% Y/Y). Over the last 2 years, CRL ...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Company aligns HemaCare Donor Center brand to streamline donor experience Charles River Laboratories International, Inc. (NYSE:CRL) today announced the launch of a new digital donor experience to enhance access to its donor centers in four distinct US geographic markets. Cha...
Summary Shares of Charles River have been hard hit by operational missteps, but shares are not cheap enough to buy yet. While its safety unit has done very well, its CDMO unit has been slow to build momentum and is unlikely to do so before 2023. Charles River's elevated floati...
Charles River Laboratories International ( NYSE: CRL ) and Nanoscope Therapeutics are collaborating for manufacturing gene therapies for vision disorders. Charles River will manufacture both plasmid DNA and viral vectors for late stage trials targeting degene...
Charles River will manufacture both plasmid DNA and viral vectors for late phase clinical trials targeting degenerative ocular diseases with no known cure Charles River Laboratories International, Inc. (NYSE: CRL) and Nanoscope Therapeutics, Inc. , a clinical-stage biote...
Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2022 financial results on Wednesday, November 2 nd , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, November 2 nd , at 9:00 a.m. ET. ...
Platform has the capability to reduce time from process development to GMP by 55 percent and deliver a drug product in fewer than 8 months nAAVigation platform will be launched at the Cell & Gene Meeting on the Mesa Charles River Laboratories International, I...
Charles River Laboratories ( NYSE: CRL ) gained in the pre-market trading Friday after Jefferies upgraded the non-clinical contract research organization (CRO) to Buy from Hold, noting the company’s prospects in the market for non-human primates (NHP). The analysts ...
News, Short Squeeze, Breakout and More Instantly...
Charles River Laboratories International Inc. Company Name:
CRL Stock Symbol:
NYSE Market:
Charles River Laboratories International Inc. Website:
Clinical trials for AAV9 gene therapy bolstered with plasmid and viral vector CDMO expertise Charles River Laboratories International, Inc. (NYSE: CRL) announced today a collaboration with the FOXG1 Research Foundation (FRF) highlighting the patient advocacy group’s model t...
Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Aut...
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2024 financial results on Wednesday, August 7 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 7 th , at 9:00 a.m. ET. Investors wi...